A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
Essen Biotech
University of Wisconsin, Madison
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
St. Jude Children's Research Hospital
University of Ulm
University of Arizona
Case Comprehensive Cancer Center
University of Rochester
Centre Antoine Lacassagne
UNC Lineberger Comprehensive Cancer Center
Institut Bergonié
Universität des Saarlandes
University Hospital Southampton NHS Foundation Trust
Dana-Farber Cancer Institute
University Health Network, Toronto
City of Hope Medical Center
University of Chicago
Case Comprehensive Cancer Center
Thomas Jefferson University
Institute of Hematology & Blood Diseases Hospital, China
Thomas Jefferson University
Columbia University
City of Hope Medical Center
Stanford University
Affiliated Hospital to Academy of Military Medical Sciences
Mayo Clinic
Affiliated Hospital of Nantong University
M.D. Anderson Cancer Center
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Australasian Leukaemia and Lymphoma Group
City of Hope Medical Center
Columbia University
University College, London
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Martin-Luther-Universität Halle-Wittenberg
University of Birmingham
Sunnybrook Health Sciences Centre
University of Nebraska
Memorial Sloan Kettering Cancer Center
University of Nebraska
Chinese PLA General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology